Natus Medical Inc  

(Public, NASDAQ:BABY)   Watch this stock  
Find more results for baby
14.42
+0.34 (2.41%)
After Hours: 14.10 -0.32 (-2.21%)
Jun 18, 5:53PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.97 - 14.67
52 week 9.65 - 15.18
Open 14.14
Vol / Avg. 0.00/180,304.00
Mkt cap 437.49M
P/E 66.71
Div/yield     -
EPS 0.22
Shares 30.34M
Beta 1.34
Inst. own 81%
Jul 22, 2013
Q2 2013 Natus Medical Incorporated Earnings Release Add to calendar
Jun 7, 2013
Natus Medical Incorporated Annual Shareholder Meeting
Jun 3, 2013
Natus Medical Incorporated at Jefferies Global Healthcare Conference - Webcast
May 21, 2013
Natus Medical Incorporated at UBS Global Healthcare Conference - Webcast
May 20, 2013
Q1 2013 Natus Medical Incorporated Earnings Conference Call - Webcast
May 20, 2013
Q1 2013 Natus Medical Incorporated Earnings Release
May 14, 2013
Natus Medical Incorporated at Bank of America Merrill Lynch Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 4.01% 1.33%
Operating margin 5.66% 1.80%
EBITD margin - 9.33%
Return on average assets 3.45% 1.10%
Return on average equity 5.10% 1.47%
Employees 1,028 -
Carbon Disclosure Rating - -

Address

1501 Industrial Road
SAN CARLOS, CA 94070
United States - Map
+1-650-8020400 (Phone)
+1-650-8020401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Natus Medical Incorporated (Natus) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company�s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn�s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus categorizes its products into three categories: Hearing, Neurology and Newborn Care. In July 2012, the Company acquired the Nicolet neurodiagnostic business from CareFusion.

Officers and directors

Robert A. Gunst Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
James B. Hawkins President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Jonathan A. Kennedy Chief Financial Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Steven J. Murphy Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Austin F. Noll III Vice President and General Manager - Neurology Strategic Business Unit
Age: 46
Bio & Compensation  - Reuters
Kenneth M. Traverso Vice President, General Manager - Newborn Care Strategic Business Unit
Age: 52
Bio & Compensation  - Reuters
D. Christopher Chung M.D. Vice President - Medical Affairs, Quality & Regulatory
Age: 49
Bio & Compensation  - Reuters
Doris E. Engibous Independent Director
Age: 58
Bio & Compensation  - Reuters
Kenneth E. Ludlum Independent Director
Age: 60
Bio & Compensation  - Reuters
Mark D. Michael Independent Director
Age: 62
Bio & Compensation  - Reuters